Totally Implantable Venous Catheters for Chemotherapy: Experience in 500 Patients

Overview

Journal Sao Paulo Med J

Specialty General Medicine

Date 2004 Nov 16

PMID 15543368

Citations 23

Authors

Nelson Wolosker

Guilherme Yazbek

Kenji Nishinari

Luiz Caetano Malavolta

Marco Antonio Munia

Marcel Langer

Antonio Eduardo Zerati

Affiliations

Soon will be listed here.

Abstract

Context: Totally implantable devices are increasingly being utilized for chemotherapy treatment of oncological patients, although few studies have been done in our environment to analyze the results obtained from the implantation and utilization of such catheters.

Objective: To study the results obtained from the implantation of totally implantable catheters in patients submitted to chemotherapy.

Type Of Study: Prospective.

Setting: Hospital do Cancer A.C. Camargo, Sao Paulo, Brazil.

Methods: 519 totally implantable catheters were placed in 500 patients submitted to chemotherapy, with preference for the use of the right external jugular vein. Evaluations were made of the early and late-stage complications and patient evolution until removal of the device, death or the end of the treatment.

Results: The prospective analysis showed an average duration of 353 days for the catheters. There were 427 (82.2%) catheters with no complications. Among the early complications observed, there were 15 pathway hematomas, 8 cases of thrombophlebitis of the distal stump of the external jugular vein and one case of pocket infection. Among the late-stage complications observed, there were 43 infectious complications (0.23/1000 days of catheter use), 11 obstructions (0.06/1000 days of catheter use) and 14 cases of deep vein thrombosis (0.07/1000 days of catheter use). Removal of 101 catheters was performed: 35 due to complications and 66 upon terminating the treatment. A total of 240 patients died while the catheter was functioning and 178 patients are still making use of the catheter.

Conclusion: The low rate of complications obtained in this study confirms the safety and convenience of the use of totally implantable accesses in patients undergoing prolonged chemotherapy regimes.

Citing Articles

Totally implantable venous access devices: A restrospective analysis of morbidity and risk factors in a hospital with multi-technique approaches.

Melo-Pinto D, Moreira-Marques T, Guerreiro E, Morais M Surg Pract Sci. 2025; 16():100237.

PMID: 39845341 PMC: 11749897. DOI: 10.1016/j.sipas.2024.100237.

A Monocentric Analysis of Implantable Ports in Cancer Treatment: Five-Year Efficacy and Safety Evaluation.

Abou-Mrad A, Marano L, Oviedo R Cancers (Basel). 2024; 16(16).

PMID: 39199575 PMC: 11352375. DOI: 10.3390/cancers16162802.

Evaluation of the position of the central venous catheter tip of implantable venous access devices in the occurrence of postoperative thrombotic and non-thrombotic complications.

Hamri H, Pop C, Mauriac S, Degreve C, Khaled C, Vouche M Support Care Cancer. 2024; 32(6):355.

PMID: 38750256 DOI: 10.1007/s00520-024-08563-7.

Standardized procedure prevents perioperative and early complications in totally implantable venous-access ports-a complication analysis of more than 1000 TIVAP implantations.

Thiel K, Kalmbach S, Maier G, Wichmann D, Schenk M, Konigsrainer A Langenbecks Arch Surg. 2022; 407(8):3755-3762.

PMID: 36070032 PMC: 9722872. DOI: 10.1007/s00423-022-02656-9.

External Jugular Venous Cutdown versus Percutaneous Technique for Chemoport Insertion in Children: A Comparative Study.

Radhakrishna V, Radhakrishnan C, Srinivasa Rao R, Kireeti G J Indian Assoc Pediatr Surg. 2022; 27(2):140-146.

PMID: 35937132 PMC: 9350643. DOI: 10.4103/jiaps.JIAPS_346_20.

References

Conlan M, Haire W, Lieberman R, Lund G, Kessinger A, Armitage J . Catheter-related thrombosis in patients with refractory lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant. 1991; 7(3):235-40. View

Harvey W, Pick T, Reed K, Solenberger R . A prospective evaluation of the Port-A-Cath implantable venous access system in chronically ill adults and children. Surg Gynecol Obstet. 1989; 169(6):495-500. View

Lokich J, Bothe Jr A, Benotti P, Moore C . Complications and management of implanted venous access catheters. J Clin Oncol. 1985; 3(5):710-7. DOI: 10.1200/JCO.1985.3.5.710. View

Raad I, Luna M, Khalil S, Costerton J, Lam C, Bodey G . The relationship between the thrombotic and infectious complications of central venous catheters. JAMA. 1994; 271(13):1014-6. View

Astagneau P, Maugat S, Tran-Minh T, Douard M, Longuet P, Maslo C . Long-term central venous catheter infection in HIV-infected and cancer patients: a multicenter cohort study. Infect Control Hosp Epidemiol. 1999; 20(7):494-8. DOI: 10.1086/501658. View

Campbell T . Central venous catheter management in patients with cancer. Int J Palliat Nurs. 2001; 6(7):331-7. DOI: 10.12968/ijpn.2000.6.7.9069. View

De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D, Morassut S . Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study. Thromb Res. 1997; 86(2):101-13. DOI: 10.1016/s0049-3848(97)00054-6. View

Monreal M, Davant E . Thrombotic complications of central venous catheters in cancer patients. Acta Haematol. 2001; 106(1-2):69-72. DOI: 10.1159/000046591. View

Abrahm J, Mullen J . A prospective study of prolonged central venous access in leukemia. JAMA. 1982; 248(21):2868-73. View

10.

HICKMAN R, Buckner C, Clift R, Sanders J, Stewart P, Thomas E . A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979; 148(6):871-5. View

11.

Biffi R, de Braud F, Orsi F, Pozzi S, Mauri S, Goldhirsch A . Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. Ann Oncol. 1998; 9(7):767-73. DOI: 10.1023/a:1008392423469. View

12.

Minassian V, Sood A, Lowe P, Sorosky J, Buller R . Longterm central venous access in gynecologic cancer patients. J Am Coll Surg. 2000; 191(4):403-9. DOI: 10.1016/s1072-7515(00)00690-6. View

13.

Gould J, Carloss H, Skinner W . Groshong catheter-associated subclavian venous thrombosis. Am J Med. 1993; 95(4):419-23. DOI: 10.1016/0002-9343(93)90312-d. View

14.

Douard M, Ardoin C, Payri L, Tarot J . [Infectious complications of long term intravenous devices: incidence, risk factors, diagnostic tools]. Pathol Biol (Paris). 1999; 47(3):288-91. View

15.

Ranson M, Oppenheim B, Jackson A, Kamthan A, Scarffe J . Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients. J Hosp Infect. 1990; 15(1):95-102. DOI: 10.1016/0195-6701(90)90025-j. View

16.

Jaeger K, Osthaus A, Heine J, Ruschulte H, Kuhlmann C, Weissbrodt H . Efficacy of a benzalkonium chloride-impregnated central venous catheter to prevent catheter-associated infection in cancer patients. Chemotherapy. 2000; 47(1):50-5. DOI: 10.1159/000048501. View

17.

Blot F, Nitenberg G, Chachaty E, Raynard B, Germann N, Antoun S . Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet. 1999; 354(9184):1071-7. DOI: 10.1016/s0140-6736(98)11134-0. View

18.

Sotir M, Lewis C, Bisher E, Ray S, Soucie J, Blumberg H . Epidemiology of device-associated infections related to a long-term implantable vascular access device. Infect Control Hosp Epidemiol. 1999; 20(3):187-91. DOI: 10.1086/501609. View

19.

Raad I, Costerton W, Sabharwal U, Sacilowski M, Anaissie E, Bodey G . Ultrastructural analysis of indwelling vascular catheters: a quantitative relationship between luminal colonization and duration of placement. J Infect Dis. 1993; 168(2):400-7. DOI: 10.1093/infdis/168.2.400. View

20.

Ballarini C, Intra M, Ceretti A, Cordovana A, Pagani M, Farina G . Complications of subcutaneous infusion port in the general oncology population. Oncology. 1999; 56(2):97-102. DOI: 10.1159/000011947. View